1. Australia Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Renerve Limited

Renerve Limited

AASX:RNV
0.09
AUD
0.00
(0.00%)
-0.04EPS
13.27MMarket Cap
Renerve Limited
ASX:RNV
(Australian Securities Exchange)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
2026
AUD
- -
- -
- -
- -
- -
Revenue per Share
-0.01
-0.01
-0.02
-0.03
-0.04
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
0.05
0.04
0.02
Book Value per Share
- -
- -
0.05
0.04
0.02
Tangible Book Value per Share
142
142
142
123
159
Basic Weighted Avg Shares
1
- -
- -
- -
1
Sales/Revenue/Turnover
-303.71
-1,709.17
-1,756.95
-1,639.23
-1,276.81
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-2
-2
-3
-4
-6
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-303.97
-1,403.39
-1,682.86
-1,374.24
-1,091.87
Profit Margin (%)
- -
- -
7
5
3
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
- -
7
5
3
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-80.46
-59.2
-133.13
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-38.86%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
49.24%
Sales/Revenue/Turnover
- -
- -
87.83%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
1

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.02
2025
- -
- -
-0.03
2026
- -
- -
-0.04

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
ReNerve Ltd. is a medical device company focused on the repair of peripheral nerve injuries. It develops, commercializes, and markets a range of biomaterial-based medical devices used in the protection, repair, and replacement of peripheral nerves during surgery. Its product portfolio includes the NervAlign Nerve Cuff, NervAlign Nerve Conduit, NervAlign Nerve Guide Matrix, and NervAlign Bionic Nerve. The company aims to improve patient outcomes by optimizing the healing environment for soft tissue repair and regeneration. ReNerve was founded by Julian Chick, Alex Adamides and David Rhodes on September 16, 2016 and is headquartered in Melbourne, Australia.